Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Get Matt Maley’s top ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1 ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare ...

The company also said its CVS Caremark pharmacy-benefit-manager business is partnering with Denmark-based Novo Nordisk A/S to “significantly increase access to Wegovy” for its members. Starting July 1 ...

CVS’ pharmacy benefit manager Caremark also reached an agreement with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...